Lowenstein represented Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) in an agreement to acquire assets of Healion Bio, Inc., including its entire portfolio of next-generation antiviral technology assets.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.
Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action.
Lowenstein also represented Tonix in 2021 in its acquisition of a new research and development center aimed at accelerating the internal discovery and development of vaccines and antiviral drugs against COVID 19, its variants, and other infectious diseases and to increase domestic R&D capability to support U.S. pandemic preparedness.
The deal team for the most recent acquisition included Michael J. Lerner, Brooke A. Gillar, Brian A. Silikovitz, Kaitlyn M. Baietto, and Christopher M. Cozzens.
